Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/13/2025 | $7.00 | Outperform → Neutral | Wedbush |
10/19/2023 | Outperform → Market Perform | TD Cowen | |
11/8/2022 | $9.00 | Buy | Canaccord Genuity |
12/15/2021 | $40.00 → $10.00 | Market Outperform | JMP Securities |
12/15/2021 | $50.00 → $27.00 | Buy | Needham |
12/14/2021 | Outperform → Mkt Perform | William Blair |
8-K - Generation Bio Co. (0001733294) (Filer)
SCHEDULE 13G/A - Generation Bio Co. (0001733294) (Subject)
10-Q - Generation Bio Co. (0001733294) (Filer)
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company's Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company's Chief Legal Officer since joini
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell-driven autoimmune diseases • Company is evaluating strategic alternatives to maximize value of its delivery system and potential therapeutics for T cell-driven autoimmune diseases for shareholders • Cash balance of $141.4M as of June 30, 2025 • Recent litigation settlement extinguishes lease liability CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's p
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-shar
Wedbush downgraded Generation Bio from Outperform to Neutral and set a new price target of $7.00
TD Cowen downgraded Generation Bio from Outperform to Market Perform
Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company's Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company's Chief Legal Officer since joini
Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it
Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)